Shanghai INT Medical Instruments Co., Ltd. will hold its annual general meeting on 28 May 2026 in Shanghai. Key resolutions include approval of the 2025 annual results, adoption of a final dividend, a sizeable capital expenditure budget for 2026 and a new share repurchase mandate.

Dividend Proposal • Board recommends a cash dividend of RMB0.23 per share (about HK$0.26). • Subject to approval, payment is scheduled on or about 30 June 2026 to shareholders on record as at 10 June 2026. • The register of members will be closed from 5 June to 10 June 2026 for dividend entitlement.

2026 Capital Expenditure Budget • Management seeks approval for a RMB604.70 million spending plan: – RMB504.40 million for external investments (acquisitions and funds); – RMB50.30 million for new and replacement production equipment; – RMB50.00 million for industrial-park construction. • Funding will come from internal resources, raised proceeds and bank loans.

Share Repurchase Mandate • Directors request authority to buy back up to 10% of issued shares during the 12-month mandate period. • Based on the current 211.20 million shares outstanding, the ceiling equals 21.12 million shares.

Corporate Governance Changes • Proposal to abolish the Supervisory Committee and transfer its functions to the Board’s Audit Committee, accompanied by extensive amendments to the Articles of Association.

Other AGM Items • Approval of 2025 directors’ and supervisory reports, audited financial statements and the 2025 profit distribution plan. • Re-appointment of KPMG and KPMG Huazhen LLP as international and domestic auditors for 2026. • Directors’ remuneration for 2026: independent non-executive directors to receive RMB120,000 each; executive and non-executive directors to be compensated only for their management roles. • Routine re-election of directors and approval of the 2026 financial budget.

Key Dates • Shareholders register closed for AGM: 28 April – 28 May 2026. • Proxy forms must reach the company or Computershare Hong Kong Investor Services no later than 24 hours before the AGM.

If approved, these measures will reinforce INT Medical’s capital management flexibility, fund strategic growth initiatives and streamline governance.